Cross-country snapshot of unvaccinated Canadian healthcare workersMany are not immune to COVID-19 conspiracy theories and misinformation. Pfizer COVID-19 vaccine unlikely to cause relapse of Guillain-Barré syndrome Study suggests minimal risk of relapse when Pfizer-BioNTech mRNA COVID-19 vaccine is given to patients with a history of GBS. Ivermectin: efficacy and safety data lacking for COVID-19 prevention or treatment Health Canada advises consumers not use veterinary or human dosage forms of ivermectin to prevent or treat COVID-19. Vaccine hesitancy highest in Alberta, racialized groups at rollout's start: survey The survey, led by researchers at Toronto's St. Michael's Hospital, was published online Tuesday in The Lancet Regional Health–Americas. One jab has almost no effect against Delta: study According to a recently published study, two shots are better than one when it comes to protection against the SARS-CoV-2 Delta, as well as other, variants of the virus. J&J: Potential HIV vaccine falls short in mid stage study The study in sub-Saharan Africa involved about 2,600 women who were deemed to be at high risk of acquiring HIV, which causes AIDS. Six things to tell patients about the Delta variant of SARS-CoV-2 Spreads faster than early forms of SARS-CoV-2 and is now the predominant variant in Canada and the United States Ontario's Vaccine Clinical Advisory Group recommends some cohorts receive third mRNA vaccine The update outlines the specific populations who would most benefit from a third or booster shot. Health Canada considering new oral antiviral for treatment of COVID-19 Merck’s molnupiravir is a twice-daily oral antiviral agent currently under study as a potential treatment for mild/moderate COVID-19. Be alert for dermatologic conditions related to COVID-19 Skin conditions may be directly related to COVID-19, or indirectly related due to use of personal protective equipment and frequent sanitization. First Previous 46 47 48 49 50 Next Last
